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Abstract 
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the 
EAACI Guidelines for Allergen Immunotherapy (AIT) for Allergic Asthma. We seek to critically assess the effectiveness, 
cost‑effectiveness and safety of AIT in the management of allergic asthma.
Methods: We will undertake a systematic review, which will involve searching international biomedical databases 
for published, in progress and unpublished evidence. Studies will be independently screened against pre‑defined 
eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and 
appropriate, quantitatively synthesised.
Discussion: The findings from this review will be used to inform the development of recommendations for EAACI’s 
Guidelines on AIT.
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Background
Asthma is a major public health problem affecting over 
300 million people worldwide [1]. Its prevalence and 
impact are particularly on the rise in urbanized regions. 
With a projected surge in the world’s urban population 
it is estimated that by 2025 an additional 100 million 
people may develop asthma [2]. Asthma is therefore set 
to become one of the world’s most prevalent chronic 
diseases.
Pathophysiologically asthma is a chronic inflammatory 
disorder of the airways leading to airflow limitation and 
remodeling [3]. The resulting signs and symptoms are 
dyspnea, cough, chest discomfort, wheezing and anxi-
ety. Based on clinical and laboratory findings, different 
phenotypes have been described [4]. The pathogenesis of 
asthma is highly complex and several disease endotypes 
have been suggested [5]. This review will focus on allergic 
asthma. Currently there is no cure for asthma available 
but symptomatic control can be achieved with inhaled 
steroids with minimal if any side-effects. Long-acting 
beta-2 agonists, antileukotrienes, theophylline, anti-IgE 
antibodies and anticholinergic drugs can be added to 
achieve asthma control in more severe cases [6].
Allergen immunotherapy (AIT) is the only effective 
anetiological treatment for respiratory allergy, which 
has the potential to change the course of the disease. Its 
immunological mechanisms of action have been demon-
strated as induction of allergen-specific immune toler-
ance. AIT for allergic asthma is a potential therapeutic 
option for well-selected patients [7].
The European Academy of Allergy and Clinical Immu-
nology (EAACI) is in the process of developing the 
EAACI Guidelines for allergen immunotherapy (AIT), 
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evidence syntheses that are being undertaken in order 
to provide a state-of-the-art synopsis of the current evi-
dence base in relation to evaluating AIT for the treatment 
of allergic asthma, allergic rhino conjunctivitis, food 
allergy and venom allergy, and allergy prevention, which 
will be used to inform the formulation of key clinical rec-
ommendations. The focus of this review is on assessing 
the effectiveness, safety and cost-effectiveness of AIT in 
the management of allergic asthma.
Methods
Search strategy
A highly sensitive search strategy has been developed, 
and validated study design filters will be applied to 
retrieve articles pertaining to the use of AIT for allergic 
asthma from electronic bibliographic databases. We have 
conceptualized the search to incorporate the four ele-
ments shown in Fig. 1.
To retrieve systematic reviews, we will use the sys-
tematic review filter developed at McMaster University 
Health Information Research Unit (HIRU) (http://hiru.
mcmaster.ca/hiru/HIRU_Hedges_MEDLINE_Strategies.
aspx#Reviews). To retrieve randomized controlled tri-
als (RCTs), we will apply the Cochrane highly sensitive 
search strategy for identifying RCTs in MEDLINE [8]. 
To retrieve case series, we will use the filter developed 
by librarians at Clinical Evidence: http://clinicalevidence.
bmj.com/x/set/static/ebm/learn/665076.html.
We will search the following databases:
  • Cochrane Library including,
• Cochrane Database of Systematic Reviews (CDSR)
•  Database of Reviews of Effectiveness (DARE)
•  CENTRAL (Trials)
•  Methods Studies
•  Health Technology Assessments (HTA)
•  Economic Evaluations Database (EED)
  • MEDLINE (OVID)
  • Embase (OVID)
  • CINAHL (Ebscohost)
  • ISI Web of Science (Thomson Web of Knowledge)
  • TRIP Database (www.tripdatabase.com)
  • Clinicaltrials.gov (NIH web).
  • Current controlled trials (www.controlled-trials.com)
  • Australian and New Zealand Clinical Trials Registry 
(http://www.anzctr.org.au)
The search strategy has been developed on OVID 
MEDLINE and then adapted for the other databases (see 
Additional file 1: Appendix S1). In all cases, the databases 
will be searched from inception to October 31, 2015. 
Additional references will be located through search-
ing the references cited by the identified studies, and 
unpublished work and research in progress will be identi-
fied through discussion with experts in the field. We will 
invite experts who are active in the field from a range of 
disciplines and regions to add to the list of included stud-
ies by identifying additional published and unpublished 
papers they are aware of and research in progress. There 
will be no language restrictions employed; where possi-
ble, all relevant literature will be translated into English.
Inclusion criteria
Patient characteristics
We will focus on studies conducted on patients of any age 
with a physician confirmed diagnosis of allergic asthma, 
plus evidence of clinically relevant allergic sensitization 
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Fig. 1 Conceptualization of systematic review of allergen immunotherapy for allergic asthma
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or specific-IgE), in combination with a history of asthma 
symptoms due to allergen exposure.
Interventions of interest
This review is focused on AIT for different allergens (e.g. 
pollens, house dust mites, animal dander, cockroach 
and moulds), administered through either subcutaneous 
(SCIT) or sublingual (SLIT) routes compared with pla-
cebo or any active comparator.
Study designs
Systematic reviews of RCTs and RCTs will be used to 
investigate effectiveness; health economic analysis will be 
used to assess cost-effectiveness; and systematic reviews, 
RCTs and case series, with a minimum of 300 patients, 
will be used to assess safety.
Study outcomes
Primary
•  Effectiveness (both short-term and long-term, where 
long-term is defined as persistence of benefit after dis-
continuation of AIT) assessed by symptom and medi-
cation scores.
Secondary
  • Asthma control
  • Asthma specific quality of life
  • Exacerbations
  • Lung function
  • Environmental exposure chamber or bronchial aller-
gen challenge
  • Safety as assessed by local and systemic reactions
  • Health economic analysis from the perspective of the 
health system/payer.
Exclusion criteria
The following exclusion criteria will be applied:
  • Reviews, discussion papers, non-research letters and 
editorials
  • Animal studies
  • Quantitative studies not employing systematic review 
or RCT techniques
  • Qualitative studies
  • Case series (less than 300 patients).
Study selection
All references will be uploaded into the systematic 
review software Distiller and undergo initial deduplica-
tion. Study titles will be independently checked by two 
reviewers according to the above selection criteria and 
categorized as: included, not included or unsure. For 
those papers in the unsure category, we will retrieve the 
abstract and re-categorize as above. Any discrepancies 
will be resolved through discussion and, if necessary, a 
third reviewer will be consulted. Full text copies of poten-
tially relevant studies will be obtained and their eligibility 
for inclusion independently assessed. Studies that do not 
fulfil all of the inclusion criteria will be excluded.
Quality assessment strategy
Quality assessments will independently be carried out on 
each study by two reviewers using the relevant version 
of the Critical Appraisal Skills Programme (CASP) qual-
ity assessment tool for systematic reviews and economic 
evaluations [9, 10]. RCTs will be assessed for generation 
of allocation sequence, concealment of allocation, base-
line outcome measurements, baseline characteristics, 
incomplete outcome data, blinding of outcome asses-
sor, protection against contamination, selective outcome 
reporting and other risks of bias using the Cochrane risk 
of bias tool. Similarly, we will use the quality assessment 
form produced by the National Institute for Health and 
Clinical Excellence (NICE) to critically appraise case 
series [11]. Any discrepancies will be resolved by discus-
sion or, if agreement cannot be reached, a third reviewer 
will arbitrate.
Data extraction, analysis and synthesis
Data will be independently extracted onto a custom-
ized data extraction sheet in Distiller by two reviewers, 
and any discrepancies will be resolved by discussion or, 
if agreement cannot be reached, by arbitration by a third 
reviewer.
A descriptive summary with summary data tables will 
be produced to summarize the literature. If clinically and 
statistically appropriate, meta-analysis using either fixed-
effect or random-effects modeling will be undertaken [8]. 
A narrative synthesis of the data will also be undertaken.
Sensitivity and subgroup analyses, and assessment 
for publication bias
Sensitivity analyses will be undertaken by comparing the 
summary estimates obtained by excluding studies judged 
to be at high risk of bias with those judged to be at low or 
moderate risk of bias.
Subgroup analyses will be undertaken to compare:
  • Children (5–11  years) versus adolescents (12–
17 years) versus adults (≥18 years)
  • SCIT versus SLIT AIT
  • Monosensitized and mono-allergic versus polysensi-
tized
  • Mild/moderate versus severe disease.
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  • Treatment duration: ≤3 versus >3 years.
Where possible, publication bias will be assessed 
through the creation of funnel plots, and tested by Egg-
er’s regression test and Begg’s rank correlation test [12, 
13].
Registration and reporting
This review will be registered with the International Pro-
spective Register of Systematic Reviews (PROSPERO): 
http://www.crd.york.ac.uk/prospero/. The Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist will be used to guide the 
reporting of the systematic review: http://www.prisma-
statement.org/.
Discussion
This review will involve systematically identifying, criti-
quing and synthesizing the evidence on the effectiveness, 
cost-effectiveness and safety of AIT for the management 
of allergic asthma. The findings from this review will be 
used to inform the development of recommendations 
for EAACI’s Guidelines on AIT. We anticipate that this 
review will report in 2016.
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